Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapies for retinal diseases. Company news centers on its ophthalmology pipeline, including KIO-301, a molecular photoswitch program for retinitis pigmentosa, choroideremia and Stargardt disease, and KIO-104, a non-steroidal DHODH inhibitor for retinal inflammation.
Recurring updates include clinical-study publications and development progress, intellectual-property coverage for KIO-100 family formulations, collaboration and regional partnership activity, research-and-development spending, capital resources, equity financing, warrant transactions and management changes. Financial releases generally pair operating results with status reports on the company’s retinal-disease programs.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported second quarter 2026 results and a pipeline update for its retinal disease programs. The company is advancing enrollment in the higher-dose cohorts of its Phase 2 ABACUS-2 trial of KIO-301 in late-stage retinitis pigmentosa and the Phase 2 KLARITY trial of KIO-104 in macular edema due to retinal inflammation. Kiora expects last-patient-first-visit in ABACUS-2 in Q1 2027 and topline data in Q3 2027, with ABACUS-2 costs fully reimbursed under its collaboration with Théa Open Innovation. Initial KLARITY data are expected in late 2026.
The company ended June 30, 2026 with approximately $16.8 million in cash and short-term investments and recorded an additional $1.1 million in collaboration receivables and $1.8 million in tax and other receivables, supporting an expected cash runway into late 2028. Kiora also secured a private placement of up to $24.0 million in gross proceeds, including $5.0 million received upfront, with further proceeds contingent on milestone-based warrant exercises. Q2 2026 research and development expenses were about $2.1 million before $1.3 million of collaboration credits, and general and administrative expenses were about $1.4 million. Net loss for the quarter was approximately $2.1 million, compared with $2.2 million in Q2 2025.
Kiora Pharmaceuticals (NASDAQ:KPRX) will take part in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.
The live presentation is scheduled for Thursday, July 9, 2026 at 2:30 p.m. EDT and will be webcast with a replay available for 90 days.
Kiora Pharmaceuticals (NASDAQ:KPRX) reported preclinical data showing its ion channel modulator KIO-300 significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model.
KIO-300, the active ingredient in Phase 2 vision-restoration drug KIO-301, reduced epileptiform event frequency and cumulative burden without impairing normal brain electrical transmission.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q1 2026 results and a clinical update. Key points: ABACUS-2 enrollment is active and nearly 50% complete; ABACUS-1 data published in Nature Medicine; KLARITY (KIO-104) is approaching a planned safety review; quarter-end cash and short-term investments were $13.9 million, with $5.0 million raised subsequent to quarter end. The company notes collaboration receivables of $1.5 million from Théa and believes it has an operational runway into late 2028.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported publication of Phase 1 ABACUS-1 results for KIO-301 in Nature Medicine on April 14, 2026. The open-label, dose-escalation study dosed 12 eyes in six participants and met the primary 30-day ocular and systemic safety endpoint with no serious adverse events.
Exploratory findings included temporal changes in functional vision, light-induced fMRI activity in visual cortex, and improved participant-reported quality-of-life; a randomized, controlled Phase 2 trial (ABACUS-2) has been initiated to evaluate higher doses and functional endpoints.
Kiora Pharmaceuticals (NASDAQ: KPRX) closed a private placement providing up to $24 million in gross proceeds, including $5.0 million upfront and up to $19 million via milestone-based warrants. The transaction closed April 6, 2026 and was priced at-the-market under Nasdaq rules.
Each share (or pre-funded warrant) sold with four short-term Tranche A-1 warrants and one Tranche A-2 warrant at a combined purchase price of $2.543. All common warrants are immediately exercisable at $1.94, and the company will file a resale registration statement covering the issued securities.
Kiora Pharmaceuticals (NASDAQ: KPRX) announced that Eric J. Daniels, M.D., MBA will depart as Chief Development Officer effective April 17, 2026, and the company has begun a search for his successor.
Kiora said it remains focused on advancing its retinal disease pipeline; enrollment continues for KIO-301 and KIO-104. According to the company, ABACUS-2 (KIO-301) cleared enrollment for the remaining 50µg cohort and initiation of the 100µg cohort, while KLARITY (KIO-104) cleared all planned safety checkpoints and continues enrolling patients.
Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q4 and full-year 2025 results and advanced two Phase 2 retinal trials: ABACUS-2 (KIO-301) and KLARITY (KIO-104).
Key facts: $17.1M cash plus $3.5M receivables, 2025 net loss $10.8M, cash runway into late 2027, Senju option agreement up to $110M, and anticipated initial clinical readouts in 2027.
Kiora Pharmaceuticals (NASDAQ: KPRX) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 3:20 p.m. ET.
A live webcast will be available on the company's investor relations website ir.kiorapharma.com, with a replay accessible for approximately 90 days.
Kiora Pharmaceuticals (NASDAQ: KPRX) appointed retina specialist Dr. Taiji Sakamoto to its Scientific Advisory Board on January 27, 2026. Dr. Sakamoto, chair of ophthalmology at Kagoshima University, will advise on clinical and scientific strategy for retinal therapeutics including non-steroidal approaches such as KIO-104. He has led research in diabetic retinopathy, retinal surgery, ocular angiogenesis, published over 460 peer-reviewed papers and held leadership roles in JRVS and international ophthalmology organizations.